Asset Details
Do you wish to reserve the book?
Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis
Do you wish to request the book?
Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis
2020
Overview
Background
Several new treatments for severe asthma have become available in the last decade; yet, little data exist to guide their use in specific patient populations.
Objective
A network meta-analysis was conducted comparing the efficacy of FDA-approved monoclonal antibody therapies in preventing exacerbations in patients with severe eosinophilic asthma.
Methods
PubMed and Ovid were searched from inception until July 2019 for randomized controlled trials that studied the efficacy of benralizumab, dupilumab, mepolizumab, and reslizumab, in preventing acute exacerbations of asthma. Studies were included if they reported data for patients with severe eosinophilic asthma (defined in this meta-analysis as absolute eosinophil count ≥ 250 cells/μL). Annualized rate ratios for asthma exacerbations (during treatment) were calculated and converted to log rate ratios. Direct and indirect treatment estimates (for inter-drug differences) were analyzed using frequentist network meta-analysis methodology in R and treatments were ranked based on
P
-scores.
Results
In total, nine studies were included in the final analysis. Network meta-analysis revealed that all drugs were superior to placebo in preventing rates of asthma exacerbation in the study population and no inter-drug differences existed. Dupilumab was found to have the greatest magnitudes of effect on decreasing log rate ratio of asthma exacerbation based on
P
-score (0.83).
Conclusion
Benralizumab, dupilumab, mepolizumab, and reslizumab are all associated with decreased asthma exacerbations in patients with eosinophilic asthma, with no significant inter-drug differences.
Publisher
Springer US,Springer,Springer Nature B.V
Subject
Anti-Asthmatic Agents - therapeutic use
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Asthma
/ Eosinophilia - physiopathology
/ Humans
/ Interleukin-13 - antagonists & inhibitors
/ Interleukin-4 Receptor alpha Subunit - antagonists & inhibitors
/ Interleukin-5 - antagonists & inhibitors
/ Interleukin-5 Receptor alpha Subunit - antagonists & inhibitors
/ Medicine
/ Patients
/ Pneumology/Respiratory System
/ Randomized Controlled Trials as Topic
/ Ratios
/ Software
/ Steroids
